# MEN1703

Source: https://onco.cc/drugs/men1703/  
OnCo record `men1703` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.

## Summary

MEN1703 (SEL24) is a small molecule (kinase inhibitor) developed by Ryvu Therapeutics. Its target is FLT3 (the sponsor names PIM/FLT3 kinase). ClinicalTrials.gov describes the intervention as: MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukaemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT06534437, plans to enrol 178 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Dapolsertib hydrochloride
- Tags: pipeline; ctgov-ingest
- Code: SEL24
- Modality: small molecule (kinase inhibitor)
- Mechanism: Small molecule (kinase inhibitor) directed at FLT3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of MEN1703: https://clinicaltrials.gov/search?intr=SEL24
- Sponsor page: https://www.ryvu.com

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [FLT3](https://onco.cc/targets/flt3/)
- companies: [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/)
- trials: [MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)](https://onco.cc/trials/nct06534437/)

---
JSON: https://onco.cc/api/v1/entities/men1703.json